TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Phase 3 Terminated
1,333 enrolled 22 charts
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
69 enrolled
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 2 Completed
109 enrolled 12 charts
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
Phase 2 Completed
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
110 enrolled 8 charts
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
62 enrolled
S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 1 Terminated
24 enrolled 10 charts
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
242 enrolled